LCTX
Lineage Cell Therapeutics, Inc.
1.30
20800 x 1.26
4100 x undefined
bid
ask
-
0.01
0.76%
12450 @ 08:53 AM
1.29 -0.01 (0.77%)
| Ytd | -22.16% | |
| 1y | 44.44% |
1.29
day range
1.33
0.93
52 week range
2.09
| Open | 1.33 | Prev Close | 1.31 | Low | 1.29 | High | 1.33 | Mkt Cap | 324.09M |
| Vol | 773.85K | Avg Vol | 1.56M | EPS | -0.29 | P/E | N/A | Forward P/E | -3.66 |
| Beta | 1.28 | Short Ratio | 35.21 | Inst. Own | 50.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 1.33 | 200-d Avg | 1.60 | 1yr Est | 4.83 |
| Income Statement | |||
| Total Revenue | 1.73M | ||
| Revenues (USD) | 1.73M | ||
| Gross Profit | 1.73M | ||
| Operating Expenses | 9.32M | ||
| Research and Development Expense | 4.23M | ||
| Selling, General and Administrative Expense | 5.08M | ||
| Operating Income | -7.59M | ||
| Net Income | -4.81M | ||
| Net Income Common Stock | -4.81M | ||
| Net Income Common Stock (USD) | -4.81M | ||
| Consolidated Income | -4.79M | ||
| Net Income to Non-Controlling Interests | 23.00K | ||
| Earnings per Basic Share | -0.02 | ||
| Earnings per Basic Share (USD) | -0.02 | ||
| Earnings per Diluted Share | -0.03 | ||
| Earning Before Interest & Taxes (EBIT) | -4.81M | ||
| Earning Before Interest & Taxes (USD) | -4.81M | ||
| Weighted Average Shares | 245.03M | ||
| Weighted Average Shares Diluted | 261.18M | ||
| Balance Sheet | |||
| Cash and Equivalents | 35.94M | ||
| Cash and Equivalents (USD) | 35.94M | ||
| Investments | 17.44M | ||
| Investments Current | 17.44M | ||
| Trade and Non-Trade Receivables | 806.00K | ||
| Current Assets | 56.16M | ||
| Property, Plant & Equipment Net | 4.62M | ||
| Total Assets | 109.53M | ||
| Debt Current | 865.00K | ||
| Total Debt | 2.39M | ||
| Current Liabilities | 8.15M | ||
| Debt Non-Current | 1.53M | ||
| Total Liabilities | 56.84M | ||
| Accumulated Retained Earnings (Deficit) | -471.81M | ||
| Accumulated Other Comprehensive Income | -3.97M | ||
| Shareholders Equity | 53.88M | ||
| Shareholders Equity (USD) | 53.88M | ||
| Assets Non-Current | 53.37M | ||
| Total Debt (USD) | 2.39M | ||
| Deferred Revenue | 14.72M | ||
| Goodwill and Intangible Assets | 42.37M | ||
| Liabilities Non-Current | 48.69M | ||
| Trade and Non-Trade Payables | 5.57M | ||
| Tax Assets | 5.80M | ||
| Tax Liabilities | 22.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 188.00K | ||
| Net Cash Flow from Financing | 5.56M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -4.85M | ||
| Capital Expenditure | -55.00K | ||
| Issuance (Purchase) of Equity Shares | 5.35M | ||
| Issuance (Repayment) of Debt Securities | -14.00K | ||
| Net Cash Flow from Investing | -2.33M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -2.27M | ||
| Net Cash Flow from Operations | -8.08M | ||
| Effect of Exchange Rate Changes on Cash | -5.00K | ||
| Share Based Compensation | 1.17M | ||